Impact of digital health on the pharmaceutical industry : will business models be reshaped by digital health?
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Value |
|---|---|---|---|
| LDR | 00000cam a22000004b 4500 | ||
| 001 | MAP20160014242 | ||
| 003 | MAP | ||
| 005 | 20160427172637.0 | ||
| 008 | 160427s2016 usa|||| ||| ||eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 084 | $a931 | ||
| 245 | 0 | 0 | $aImpact of digital health on the pharmaceutical industry$b: will business models be reshaped by digital health? |
| 260 | $aBoston [etc.]$bArthur D. Little$ccop. 2016 | ||
| 520 | $aDigital health will transform the business models of the Pharmaceutical industry. Although many companies have not yet formulated a concise Digital Health strategy, industry executives expect that by 2020, Digital Health will enable Pharmaceutical companies to activate new business segments as well as to significantly improve their competitive advantage. This is the result of a global survey conducted in the Pharmaceutical industry by Arthur D. Little and the Karlsruher Institute of Technology (KIT) to capture the current thinking and the expectations regarding the transformative impact of Digital Health. The study results indicate that by 2020 the business model of the Pharmaceutical industry will be reshaped by Digital Health | ||
| 650 | 4 | $0MAPA20080539771$aSalud | |
| 650 | 4 | $0MAPA20080586546$aNuevas tecnologías | |
| 650 | 4 | $0MAPA20140009749$aConectividad | |
| 650 | 4 | $0MAPA20140010080$aRecursos genéticos | |
| 650 | 4 | $0MAPA20080606633$aIndustria farmacéutica | |
| 650 | 4 | $0MAPA20110024864$aModelos de negocio | |
| 650 | $0MAPA20160013733$aSalud Digital | ||
| 710 | 2 | $0MAPA20080440602$aArthur D. Little | |
| 710 | 2 | $0MAPA20160006001$aKarlsruher Institute of Technology |